一个随机的,安慰剂对照试验,评估过度使用kaempferol aglycone的安全性
Minoru Akiyama1, Tsubasa Mizokami1, Hikaru Ito1
1Saga Nutraceuticals Research Institute Otsuka Pharmaceutical Co., Ltd. Kanzaki-gun Japan.
Food science & nutrition
|September 13, 2023
概括
这项研究发现,每天50毫克的kaempferol (KMP) 甘氨酸补充剂对健康成年人来说在四周内是安全的. 没有观察到任何不良影响,支持KMP.
科学领域:
- 营养科学 营养科学
- 药理学 药理学是指药理学的学科.
- 临床毒理学 临床毒理学
背景情况:
- 凯姆费醇 (KMP) 是一种在水果和蔬菜中发现的黄类化合物,具有已记录的临床前益处.
- 流行病学研究表明,富含KMP的食物可以降低癌症和心血管疾病的风险.
- 缺乏KMP糖的临床安全数据,特别是在高剂量时.
研究的目的:
- 评估健康成年人每日高剂量凯姆菲罗尔 (KMP) 甘的安全性和耐受性.
- 通过全面的临床和实验室参数来评估潜在的毒性.
- 建立KMP糖补充剂的安全概况.
主要方法:
- 一个随机,双盲,安慰剂对照试验超过4周.
- 参与者 (n=48) 每天接受50mg的KMP甘氨酸或安慰剂.
- 通过人体测量,血压,血液学,血液生物化学,尿液分析和不良事件监测来评估安全性.
主要成果:
- 与安慰剂相比,在KMP组中没有观察到人类测量或血压的显著变化.
- 所有参与者的血液学,血液生物化学和尿液参数都保持在正常范围内.
- 没有报告与KMP甘氨酸管理相关的不良事件.
结论:
- 在健康的成年人中,每天服用50毫克的kaempferol (KMP) aglycone4周是安全的,并且能很好地容忍.
- 这种高剂量,大约是估计的饮食摄入量的五倍,没有引起不良反应.
- 这些发现支持在研究的参数内补充KMP甘氨酸的安全性.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.7K
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
2.0K
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
147
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
147
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K